• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C1q:通过亲和色谱法从人血清中高产率分离及高灵敏度溶血测定法的开发

C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay.

作者信息

Kolb W P, Kolb L M, Podack E R

出版信息

J Immunol. 1979 May;122(5):2103-11.

PMID:109524
Abstract

C1q, a subcomponent of the first component of complement, has been isolated from human serum in fully hemolytically active form by affinity column chromatography and gel filtration with Bio-Gel A-5M. The affinity column was prepared by covalent coupling of purified human IgG to CNBr-activated Sepharose 4B. Final yields of C1q ranged from 25 to 40% with 650- 890-fold purification based on recovery of hemolytic activity. The preparations were free of contaminating serum proteins as judged by SDS-polyacrylamide gel electrophoretic and immunochemical criteria. The final C1q preparations were also devoid of any demonstrable C1q-inhibitor activity. A C1q-depleted reagent (C1qD) was obtained from the nonabsorbed protein containing fractions of the human IgG-Sepharose 4B affinity column and utilized in conjunction with sensitized sheep erythrocytes (EA) for the detection and quantitation of C1q hemolytic activity. Employing optimal quantities of C1qD in the hemolytic assay mixture, the highly purified C1q preparations contained 0.5 to 1 x 10(13) effective molecules/mg and 0.5 to 1 x 10(12) effective C1q molecules/ml of human serum. This assay would therefore reproducibly detect less than 1 ng of C1q hemolytic activity.

摘要

补体第一成分的亚成分C1q,已通过亲和柱色谱法和使用Bio-Gel A-5M的凝胶过滤,以完全溶血活性形式从人血清中分离出来。亲和柱是通过将纯化的人IgG共价偶联到溴化氰活化的琼脂糖4B上制备的。基于溶血活性的回收率,C1q的最终产率在25%至40%之间,纯化倍数为650 - 890倍。根据SDS - 聚丙烯酰胺凝胶电泳和免疫化学标准判断,制备物不含污染的血清蛋白。最终的C1q制备物也没有任何可检测到的C1q抑制活性。从人IgG - 琼脂糖4B亲和柱的未吸附蛋白部分获得了C1q缺失试剂(C1qD),并与致敏绵羊红细胞(EA)一起用于检测和定量C1q溶血活性。在溶血测定混合物中使用最佳量的C1qD,高度纯化的C1q制备物每毫克含有0.5至1×10¹³个有效分子,每毫升人血清含有0.5至1×10¹²个有效C1q分子。因此,该测定法可重复检测到少于1 ng的C1q溶血活性。

相似文献

1
C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay.C1q:通过亲和色谱法从人血清中高产率分离及高灵敏度溶血测定法的开发
J Immunol. 1979 May;122(5):2103-11.
2
Immunoadsorbent affinity purification of the fifth component (C5) of human complement and development of a highly sensitive hemolytic assay.人补体第五成分(C5)的免疫吸附亲和纯化及高灵敏度溶血试验的开发。
J Immunol Methods. 1980;35(3-4):319-35. doi: 10.1016/0022-1759(80)90258-6.
3
Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.犬补体1q亚组分的纯化、特性鉴定及其在用于检测免疫复合物的¹²⁵I-C1q结合试验中的应用。
Am J Vet Res. 1988 Jun;49(6):865-9.
4
The first component of complement. I. Purification and properties of native C1.补体的第一成分。I. 天然C1的纯化及特性
J Immunol. 1980 Jul;125(1):390-5.
5
The macromolecular structure of the first component of complement.补体第一成分的大分子结构。
J Immunol. 1975 Aug;115(2):488-94.
6
[Stepwise dissociation of subcomponents of C1, the first component of human complement, upon activation on an affinity sorbent].[人补体第一成分C1在亲和吸附剂上激活后各亚组分的逐步解离]
Biokhimiia. 1989 Oct;54(10):1745-51.
7
Further studies on the identification of the subcomponents of the first component of complement after affinity chromatography of human serum on IgG-sepharose.关于人血清在IgG-琼脂糖凝胶上进行亲和层析后补体第一成分亚组分鉴定的进一步研究。
J Immunol. 1977 May;118(5):1722-7.
8
Physicochemical and functional characterization of the C1r subunit of the first complement component.补体第一成分C1r亚基的物理化学及功能特性
J Immunol. 1976 Feb;116(2):496-503.
9
[Binding and activation of the first component of human complement on artificial matrices].
Bioorg Khim. 1984 Dec;10(12):1629-38.
10
Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.大肠杆菌C1q结合蛋白对补体C1第一成分溶血活性的抑制作用。
J Immunol. 1996 Jun 1;156(11):4466-73.

引用本文的文献

1
Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma.通过从人血浆中大规模耗尽 IgG 和 IgM 生成通用人类补体源。
Methods Mol Biol. 2022;2414:341-362. doi: 10.1007/978-1-0716-1900-1_18.
2
Production, characterization, and applications of monoclonal antibodies reactive with soybean nodule xanthine dehydrogenase.大豆根瘤黄嘌呤脱氢酶单克隆抗体的制备、鉴定及应用。
Plant Physiol. 1986 Apr;80(4):965-71. doi: 10.1104/pp.80.4.965.
3
Novel collectin/C1q receptor mediates mast cell activation and innate immunity.
新型凝集素/C1q 受体介导肥大细胞活化和固有免疫。
Blood. 2006 Jan 1;107(1):143-50. doi: 10.1182/blood-2005-06-2218. Epub 2005 Sep 15.
4
Experimental transmission of Neisseria gonorrhoeae from pregnant rat to fetus.淋病奈瑟菌从妊娠大鼠到胎儿的实验性传播。
Infect Immun. 1999 Sep;67(9):4974-6. doi: 10.1128/IAI.67.9.4974-4976.1999.
5
Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines.色素沉着性干皮病细胞系中不依赖抗体的经典补体途径激活及同源C3沉积
Clin Exp Immunol. 1999 Jun;116(3):547-53. doi: 10.1046/j.1365-2249.1999.00923.x.
6
Activation of the complement classical pathway (C1q binding) by mesophilic Aeromonas hydrophila outer membrane protein.嗜温性嗜水气单胞菌外膜蛋白对补体经典途径的激活(C1q结合)
Infect Immun. 1998 Aug;66(8):3825-31. doi: 10.1128/IAI.66.8.3825-3831.1998.
7
Complement-mediated serum sensitivity among spirochetes that cause Lyme disease.引起莱姆病的螺旋体中补体介导的血清敏感性。
Infect Immun. 1997 Apr;65(4):1228-36. doi: 10.1128/iai.65.4.1228-1236.1997.
8
Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK36.补体亚成分C1q与肺炎克雷伯菌孔蛋白OmpK36之间的相互作用
Infect Immun. 1996 Nov;64(11):4719-25. doi: 10.1128/iai.64.11.4719-4725.1996.
9
C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins.肺炎克雷伯菌外膜蛋白对补体经典途径的C1q结合与激活作用。
Infect Immun. 1993 Mar;61(3):852-60. doi: 10.1128/iai.61.3.852-860.1993.
10
A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.血浆蛋白聚糖C1q抑制剂的一种独特特性。其与纤维蛋白原结合导致抗凝状态。
J Clin Invest. 1994 Jan;93(1):303-10. doi: 10.1172/JCI116960.